The Relationship Between Systemic Inflammation and Chronic Pain in Patients with Psoriasis: Evaluating the Efficacy of Analgesic Therapies
DOI:
https://doi.org/10.36489/nursing.2025v30i326p11194-11201Keywords:
Psoriasis, Systemic Inflammation, Chronic Pain, Analgesic Therapy, CytokinesAbstract
Psoriasis, traditionally recognized as a dermatological disease, is now understood as a systemic inflammatory condition with multiple manifestations, including chronic musculoskeletal pain. This article aims to explore the correlation between systemic inflammation and the mechanisms of chronic pain in patients with psoriasis, as well as evaluate the effectiveness of analgesic therapies used to manage these symptoms. Recent studies on the role of inflammatory cytokines, such as TNF-α, IL-6, and IL-17, in the development of pain are analyzed, along with pharmacological and non-pharmacological analgesic interventions. It is concluded that controlling systemic inflammation can significantly reduce chronic pain, reinforcing the importance of an integrated approach among rheumatologists, dermatologists, and pain specialists.
Metrics
References
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301–15.
Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–55.
Mease PJ, Armstrong AW. Managing patients with psoriatic disease: The diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74(4):423–41.
Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–94.
Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273–84.
Taylor WJ, Mease PJ, Helliwell PS, et al. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–73.
Kavanaugh A, Mease PJ, Reimold A, et al. Comparison of ixekizumab and adalimumab for the treatment of biologic-naive patients with psoriatic arthritis: Results from a randomized, controlled trial. Arthritis Rheumatol. 2020;72(1):49–62.
Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64 Suppl 2:ii14–7.
Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2016;75(3):499–510.
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.
McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti–interleukin-17A monoclonal antibody, in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329–39.
Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34(3):J314–21.
Ogdie A, Weiss P. The Epidemiology of Psoriatic Arthritis. Rheum Dis Clin North Am. 2015;41(4):545–68.
Fala L. Taltz (Ixekizumab): A IL-17A Monoclonal Antibody Approved for the Treatment of Adults with Active Psoriatic Arthritis. Am Health Drug Benefits. 2018;11(7):353–7.
Fitzgerald O, Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther. 2009;11(1):214.
Wu JJ, Strober BE, Hansen PR, et al. Effects of interleukin-17 inhibitors on cardiovascular outcomes in patients with psoriasis or psoriatic arthritis: A systematic review. J Am Acad Dermatol. 2020;82(6):1490–500.
Zis P, Vasileiou I, Siafakas N. Pain in patients with psoriatic disease: A review. Rheumatol Int. 2020;40(2):157–64.
Coates LC, Helliwell PS. Treating to target in psoriatic arthritis: How to implement in clinical practice. Ann Rheum Dis. 2016;75(4):640–3.
Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377(9783):2127–37.
Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med. 2017;376(10):957–70.
